Gerald E. Quirk - 30 Sep 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal & Compliance Offic
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
30 Sep 2024
Net transactions value
-$6,510
Form type
4
Filing time
02 Oct 2024, 17:00:05 UTC
Previous filing
02 Apr 2024
Next filing
20 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +10,000 +25% 49,757 30 Sep 2024 Direct F1
transaction SYRS Common Stock Tax liability $6,510 -3,100 -6.2% $2.10 46,657 30 Sep 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -10,000 -33% $0.000000 20,000 30 Sep 2024 Common Stock 10,000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding on a restricted stock unit release.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on September 12, 2023. These restricted stock units vested as to one third (1/3rd) of the shares underlying the award on September 30, 2024, and are scheduled to vest as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.